Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate.

Guo H, Zhang X, Tang S, Zhang S.

Ren Fail. 2013;35(10):1455-64. doi: 10.3109/0886022X.2013.828365. Epub 2013 Sep 2. Review.

PMID:
23992043
2.

Efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia patients receiving dialysis--a systematic review and meta-analysis of randomized controlled trials.

Huang W, Liu J, Tang Y, Gao X, Di B, Zhang F.

Curr Med Res Opin. 2014 Jan;30(1):99-108. doi: 10.1185/03007995.2013.838551. Epub 2013 Oct 9. Review.

PMID:
24063635
3.

One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.

Shigematsu T; Lanthanum Carbonate Research Group..

Ther Apher Dial. 2010 Feb;14(1):12-9. doi: 10.1111/j.1744-9987.2009.00697.x.

PMID:
20438515
4.

Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.

Shigematsu T, Ohya M, Negi S, Masumoto AR, Nakashima YM, Iwatani Y, Moribata MK, Yamanaka S, Tatsuta K, Mima T.

Contrib Nephrol. 2015;185:42-55. doi: 10.1159/000380969. Epub 2015 May 19.

PMID:
26023014
5.

Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.

Shigematsu T; Lanthanum Carbonate Research Group..

Ther Apher Dial. 2008 Feb;12(1):55-61. doi: 10.1111/j.1744-9987.2007.00541.x.

PMID:
18257813
6.

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.

Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF.

Am J Kidney Dis. 2009 Oct;54(4):619-37. doi: 10.1053/j.ajkd.2009.06.004. Epub 2009 Aug 18. Review.

PMID:
19692157
7.

Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.

Lee YK, Choi HY, Shin SK, Lee HY.

Clin Nephrol. 2013 Feb;79(2):136-42. doi: 10.5414/CN107362.

PMID:
23211335
9.

Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis.

Zhai CJ, Yang XW, Sun J, Wang R.

Int Urol Nephrol. 2015 Mar;47(3):527-35. doi: 10.1007/s11255-014-0876-x. Epub 2014 Nov 16. Review.

PMID:
25399356
10.

Lanthanum carbonate: safety data after 10 years.

Hutchison AJ, Wilson RJ, Garafola S, Copley JB.

Nephrology (Carlton). 2016 Dec;21(12):987-994. doi: 10.1111/nep.12864. Review.

12.

Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.

Vegter S, Tolley K, Keith MS, Lok CE, Soroka SD, Morton AR.

Clin Ther. 2012 Jul;34(7):1531-43. doi: 10.1016/j.clinthera.2012.06.006. Epub 2012 Jun 27.

PMID:
22742885
13.

Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate.

Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A.

Nephron Clin Pract. 2005;100(1):c8-19. Epub 2005 Apr 4.

PMID:
15809508
14.

Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.

Park H, Rascati KL, Keith MS, Hodgkins P, Smyth M, Goldsmith D, Akehurst R.

Value Health. 2011 Dec;14(8):1002-9. doi: 10.1016/j.jval.2011.05.043. Epub 2011 Jul 28.

15.
16.

Lanthanum carbonate: a postmarketing observational study of efficacy and safety.

RombolĂ  G, Londrino F, Corbani V, Falqui V, Ardini M, Zattera T; Liguria and Toscana Lanthanum Experience (LITOLAE) Group..

J Nephrol. 2012 Jul-Aug;25(4):490-6. doi: 10.5301/jn.5000118.

PMID:
22476966
17.

Lanthanum carbonate for hyperphosphatemia in patients on peritoneal dialysis.

Ohno M, Ohashi H, Oda H, Yokoyama H, Okada M, Nagaya M, Izumi K, Ito H, Katoh S.

Perit Dial Int. 2013 May-Jun;33(3):297-303. doi: 10.3747/pdi.2012.00600. Epub 2012 Dec 3.

18.

A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.

D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME.

Kidney Int Suppl. 2003 Jun;(85):S73-8.

PMID:
12753271
19.

A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.

Sprague SM.

Curr Med Res Opin. 2007 Dec;23(12):3167-75. Review. Erratum in: Curr Med Res Opin. 2008 Mar;24(3):708.

PMID:
17991307
20.

A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.

Prajapati VA, Galani VJ, Shah PR.

Saudi J Kidney Dis Transpl. 2014 May;25(3):530-8.

Supplemental Content

Support Center